We List Some of the Legal Liability Allegations Regarding Drug Company Actions and Failures
(Posted by Tom Lamb at Drug Injury Watch)
During the past several weeks, Ozempic vision loss lawsuits have been filed by patients against drug company Novo Nordisk for its alleged failure to warn about nonarteritic anterior ischemic optic neuropathy (NAION). We point out that the current drug label for Ozempic does not warn about NAION as a possible eye-related side effect.
We have been investigating possible legal cases for patients who used Ozempic (semaglutide is its active ingredient) and then developed vision loss and blindness due to NAION. In addition to these Ozempic vision loss lawsuits, we expect similar vision loss lawsuits to be filed that will involve Rybelsus and Wegovy, two other semaglutide-containing drugs from Novo Nordisk. Like Ozempic, the current drug labels for Rybelsus and Wegovy do not warn about NAION as a possible eye-related side effect.
We have explored the medical aspects of these drug injury lawsuits against Novo Nordisk in our earlier articles about vision loss and blindness due to NAION linked to their semaglutide-containing drugs, which at present are Ozempic, Rybelsus, and Wegovy. You may want to review one or more of these articles for some background:
- March 2025 Medical Article About Blindness or Vision Loss Linked to Ozempic and Rybelsus Use by Diabetes Patients (3/31/25)
- Ozempic Vision Problems From Semaglutide Apply to Wegovy and Rybelsus, Also (2/21/25)
- Novo Nordisk Semaglutide Drug Ozempic Linked to Vision Loss, Doubling the Risk: December 2024 Update (12/18/24)
- Wegovy, Rybelsus, and Ozempic Eye Side Effects: Semaglutide Linked to NAION (7/5/24)
__________________________________________________________________
Ozempic / Wegovy / Rybelsus
Free Case Evaluation
Strictly Confidential, No Obligation.
__________________________________________________________________
Next, we present a list of some legal liability allegations made in recently filed Ozempic vision loss lawsuits. This list of legal liability allegations concerning drug company actions or failures will likely change as more is learned during the litigation discovery process.
- Ozempic is an injectable prescription medication containing semaglutide that was approved by the FDA for use to control blood sugar in adults with type 2 diabetes.
- The drug company knew or should have known -- based on preclinical trials, premarket clinical trials, post-market surveillance, and adverse event reports of nonarteritic anterior ischemic optic neuropathy (NAION) being associated with Ozempic or other semaglutide drugs -- that there was reasonable evidence of a causal association between the use of Ozempic and NAION.
- Despite this available information, the drug company has failed to warn patients about the risk of developing NAION associated with Ozempic.
- Instead, the drug company worked to expand the market for Ozempic by encouraging extensive "off-label" use of Ozempic as a weight-loss medication.
- As part of their efforts, the drug company targeted users of other diabetes medications by pointing to a prospective added benefit of weight loss for Ozempic. That conduct wrongfully enticed users of those other diabetes medications to switch to Ozempic, patients who never would have done so but for this "off-label" promotion of Ozempic by the drug company.
- A patient who suffered vision loss due to NAION would not have used Ozempic -- whether for type 2 diabetes treatment or as a weight-loss medication -- if they had been provided a full and clear warning by the drug company about the risk of developing NAION associated with Ozempic.
Let us know if we can assist you with an Ozempic vision loss lawsuit involving NAION (nonarteritic anterior ischemic optic neuropathy). Likewise, if you or someone you know has developed vision loss or blindness while using Rybelsus or Wegovy, and is interested in filing a possible drug injury lawsuit against Novo Nordisk.
DrugInjuryLaw.com: Medical & Legal Information About Drug Side Effects
Drug Injury Case Evaluation - Free. Confidential. No Obligation.